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Figure 1: (a) M512 array, (b) M512 dosimetry acquisition of 
1x1cm2 field, (c) Passive M512 MR imaged at 3T, blue circles 
indicate fiducials (d) MR image of water phantom imaged 
without dosimeter noise suppression, (e) MR image of water 
phantom imaged with dosimeter noise suppression. 
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Purpose: There is an important need to improve the 
effectiveness of radio-chemotherapy (RTCT) for cervical 
cancer. These tumors recruit myeloid cells from the bone 
marrow via the CXCL12/CXCR4 pathway, which in turn 
influence vascular function and radiotherapy response. The 
objective of this study was to explore combined treatment 
with Plerixafor (a CXCL12/CXCR4 inhibitor) and standard 
RTCT on primary tumor control and the development of 
metastases, using orthotopic primary xenografts derived 
directly from patients with cervical cancer. 
Materials/Methods: Two primary cervix xenografts (OCICx13 
and OCICx20) were grown in the cervices of immune deficient 
mice.  These tumor models have been shown to mirror the 
clinical and biological behavior of cervical cancer in patients. 
To simulate clinical treatment, image-guided radiotherapy 
(30 Gy in 15 daily fractions) and concurrent weekly cisplatin 
(4 mg/kg) were administered, with or without Plerixafor (5 
mg/kg/day). The primary endpoints were tumor growth 
delay, the frequency of lymph node metastases and animal 
survival. Chemokine expression and neutrophil recruitment 
were evaluated by immunohistochemistry. Acute gut toxicity 
was assessed using the crypt cell assay. Blood and normal 
organs were examined for late toxicity. 
Results: The combination of RTCT and Plerixafor produced 
substantial tumor growth delay, reduced metastases and 
improved survival compared to standard RTCT alone in 
patient-derived xenograft models. There was a reduction in 
chemokine signaling (CXCL12/CXCR4) and myeloid cell 
infiltration (GCSF, CD11b) with combination treatment 
compared to RTCT alone. There was no effect of Plerixafor 
on acute GI toxicity, nor were there changes in blood counts 
or organ morphology to indicate increased late hematological 
or normal tissue toxicity.  
Conclusion: This preclinical study demonstrates that the 
addition of Plerixafor to standard RTCT for cervical cancer 
improves local tumor control and reduced metastases with no 
increase in toxicity. Plerixafor is commercially available for 
other indications, which will facilitate translation of these 
findings to phase I/II clinical studies. 
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Curative 3D standard external beam radiotherapy (EBRT) for 
prostate cancer has been able to improve disease control 
with dose escalation during the last 15 years though against 
the token of significant toxicity. Exploring changes in 
fractionation, doses-distribution optimization with modulated 
RT, and reducing CTV-PTV safety margins due to off- or on-
line imaging before or during irradiation, may be alternatives 
worth to be implemented in order to reach the highest 
possible toxicity-free cure rates. 
Accurate imaging helping to better define the irradiation 
target/s (e.g., multiparametric MRI, PET-CT/MRI, SPECT); 
modulated EBRT optimizing the dose distribution; and image 
guided RT (e.g., kV imaging, CBCT, fiducial markers, 
transponders, endorectal balloons, recto-prostatic spacers) 
controlling for patient repositioning and organ motion are 
presently available allowing the implementation of high 
precision treatment techniques.  
Biomathematical modeling has helped to better understand 
the very special dose-response relationships of EBRT on 
prostate cancer concerning fractionation sensitivity (low α/β 
value), overall treatment time (tumor cell repopulation 
kinetics), and fraction delivery time (potential biological 
effective dose modifier). All these factors are rather 
suggestive that prostate cancer patients, especially those 
with low- or intermediate-risk disease, can be better treated 
with “more” dose/fraction, “less” number of fractions, and a 
“shorter” time protraction and delivery time per fraction. 
Two opposed modalities conceived to deliver large doses in 
few fractions are either stereotactic body RT (SBRT) or high-
dose rate brachytherapy (HDR-BT) given alone or as a boost. 
The latter procedure may be limited by dose inhomogeneities 
and geographical misses. Even a small underdosage of the 
target or a heterogeneous dose-rate delivery may have a 
negative influence on outcome. This seems to be especially 
determinant for tumors with very low α/β values as it is the 
case for prostate cancer. Thus, SBRT may be theoretically 
more advantageous because the radiobiological reliability of 
a homogeneous dose distribution compared to HDR-BT, 
besides being less invasive and probably less costly.  
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Proton radiotherapy provides a promising and emerging 
treatment approach for cancer patients. However, 
understanding of the differences in terms of DNA damage and 
cell proliferation post-proton irradiation is relatively poor. 
The purpose of this study was to evaluate DNA damage 
induced by proton beams using various cytogenetic and 
molecular methods. 
